ATMOSPHERE
Aug 24 2021
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ATMOSPHERE)
Read MorePEP
Aug 24 2021
Patient Experience and Preference (PEP) Study in nAMD and DME Sponsor: Hoffmann-La Roche Ltd
Read MoreBIM2
Dec 01 2020
To identify whether genetic variation or polymorphism in genes that impact angiogenesis can be identified as biomarkers for responsiveness to anti-VEGF therapy in patients with neovascular age-related macular degeneration.
Read MoreCATALINA
Dec 01 2020
A Phase II Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (CATALINA) Sponsor: NGM Biopharmaceuticals, Inc.…
Read MoreTALON
Sep 28 2020
A 64-Week, Two-Arm, Randomized, Double-Masked, Multi-Center, Phase IIIb Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Aflibercept 2 mg in a Treat-To-Control Regimen in Patients with Neovascular Age-Related Macular Degeneration (TALON)…
Read MorePULSAR
Sep 28 2020
Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration (PULSAR)
Read More
7 Ways to Protect Your Eyes from Age-Related Macular Degeneration
Feb 14 2020
Age-related macular degeneration (AMD) is one of the leading causes of blindness over age 50, affecting about 2.1 million people nationwide. Early diagnosis and treatment are the keys to preventing vision loss. AMD is a…
Read MoreIONIS-FB-LRx
Jun 12 2019
The purpose of the study is to evaluate the effect of IONIS-FB-LRx on the rate of change of the area of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) measured by fundus autofluorescence (FAF).…
Read MoreDERBY/GALE
Jun 12 2019
A Phase III, Multi-Center, Randomized, Double-Masked, Sham Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (DERBY)
Read More